June 16, 2020 | Deborah Kotz
Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
Wednesday, July 07, 2021
Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.
Wednesday, June 09, 2021
Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.
Monday, March 29, 2021
Cancer Drug Lessens the Toxicity of a Protein from the Virus that Causes Covid-19, UM School of Medicine Study Finds
University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2—the virus that causes COVID-19 – and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In their experiments in fruit flies and human cell lines, the team discovered the cell process that the virus hijacks, illuminating new potential candidate drugs that could be tested for treating severe COVID-19 disease patients. Their findings were published in two studies simultaneously on March 25 in Cell & Bioscience, a Springer Nature journal.
Tuesday, March 16, 2021
New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel
Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.
Friday, February 05, 2021
UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests
Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.
Thursday, January 21, 2021
On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.
Tuesday, January 05, 2021
Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.
Tuesday, January 05, 2021
University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate
Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.
Tuesday, December 22, 2020
Largest Study of Its Kind Identifies Which COVID-19 Patients Face the Greatest Risk of Mortality During Hospitalization
Hospitalized COVID-19 patients have a greater risk of dying if they are men or if they are obese or have complications from diabetes or hypertension, according to a new study conducted by University of Maryland School of Medicine (UMSOM) researchers. In a study published in the journal Clinical Infectious Diseases, the researchers evaluated nearly 67,000 hospitalized COVID-19 patients in 613 hospitals across the country to determine the link between certain common patient characteristics and the risk of dying from COVID-19. Their analysis found that men had a 30 percent higher risk of dying compared to women of the same age and health status. Hospitalized patients who were obese, had hypertension or poorly managed diabetes had a higher risk of dying compared to those who did not have these conditions. Those aged 20 to 39 with these conditions had the biggest difference in their risk of dying compared to their healthier peers.
Thursday, November 19, 2020
Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine
Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.
Friday, November 13, 2020
UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses
Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.
Thursday, October 22, 2020
New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients
Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM). Aspirin takers were less likely to be placed in the intensive care unit (ICU) or hooked up to a mechanical ventilator, and they were more likely to survive the infection compared to hospitalized patients who were not taking aspirin, The study, published today in the journal Anesthesia and Analgesia, provides “cautious optimism,” the researchers say, for an inexpensive, accessible medication with a well-known safety profile that could help prevent severe complications.
Monday, June 15, 2020
UM School of Medicine Researchers Help Identify Potent Antibody Cocktail with Potential to Treat COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published today in the journal Science. The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.
Tuesday, June 02, 2020
UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa
The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.
Monday, June 01, 2020
In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.
Thursday, May 28, 2020
UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.
Thursday, May 21, 2020
UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.
Tuesday, May 05, 2020
In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Thursday, April 23, 2020
Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Friday, April 10, 2020
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.
Friday, October 18, 2019
Diabetes Worsens Respiratory Illness Due to Abnormal Immune Response, UM School of Medicine Study Finds
Since the Middle East respiratory syndrome coronavirus (MERS-CoV) first emerged in Saudi Arabia in 2012, there have been more than 2,400 confirmed cases of the infection, resulting in greater than 800 deaths – an alarming fatality rate of 35 percent. For this reason, researchers have been eager to identify any risk factors that contribute to the development of severe or lethal disease. Current clinical evidence points to diabetes as a major risk factor in addition to other comorbidities including kidney disease, heart disease, and lung disease.
Tuesday, December 06, 2016
In a new study, University of Maryland School of Medicine (UM SOM) researchers have modified a rabies virus, so that it has a protein from the MERS virus; this altered virus works as a 2-for-1 vaccine that protects mice against both Middle East Respiratory Syndrome (MERS) and rabies.
Monday, February 08, 2016
A multi-disciplinary group of researchers at the University of Maryland School of Medicine (UM SOM) have for the first time determined the genetic makeup of various strains of E. coli, which every year kills hundreds of thousands of people around the world.
Friday, April 14, 2000
The COVID-19 pandemic has changed many aspects of our lives, from the way we shop and eat to how we connect with family and friends. While the virus itself has had strong and sometimes devastating effects on our community, the fear of its potential impact continues to influence responses and even cripple thoughts and actions.